These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Multiple sclerosis. Ford H; Nicholas R Clin Evid; 2005 Dec; (14):1637-51. PubMed ID: 16620466 [No Abstract] [Full Text] [Related]
8. Immunotherapy of multiple sclerosis: where are we? Where should we go? Martin R; Stürzebecher CS; McFarland HF Nat Immunol; 2001 Sep; 2(9):785-8. PubMed ID: 11526386 [No Abstract] [Full Text] [Related]
12. [Will there soon be a sub-type specific treatment? New approaches to multiple sclerosis therapy]. MMW Fortschr Med; 2008 Apr; 150(15):17. PubMed ID: 18510111 [No Abstract] [Full Text] [Related]
13. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]. Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317 [No Abstract] [Full Text] [Related]
15. Activation of myelin reactive T cells in multiple sclerosis: a possible role for T cell degeneracy? Stinissen P; Hellings N Eur J Immunol; 2008 May; 38(5):1190-3. PubMed ID: 18425726 [TBL] [Abstract][Full Text] [Related]
16. A new treatment for multiple sclerosis. Piascik P Am Pharm; 1993 Dec; NS33(12):25-6. PubMed ID: 8304268 [No Abstract] [Full Text] [Related]
17. How should we proceed with disease-modifying treatments for multiple sclerosis? Andersson PB; Waubant E; Goodkin DE Lancet; 1997 Mar; 349(9052):586-7. PubMed ID: 9057726 [No Abstract] [Full Text] [Related]
18. [Drug therapy of multiple sclerosis]. Kinnunen E Duodecim; 1999; 115(4):403-7. PubMed ID: 11830889 [No Abstract] [Full Text] [Related]
19. [Causal therapy of multiple sclerosis]. Pöhlau D; Rieks M; Postert T; Hoffmann V; Przuntek H Dtsch Med Wochenschr; 1996 Nov; 121(45):1407-14. PubMed ID: 8964231 [No Abstract] [Full Text] [Related]